The atrial peptide system in cardiac disease

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Atrial natriuretic factor (ANF) is a peptide hormone of cardiac origin, released in response to atrial distention, that increases sodium excretion, inhibits the renin-angiotensin-aldosterone (RAA) system, and decreases arterial pressure. Congestive heart failure (CHF) is a clinical syndrome that is characterized by chronic atrial distention, sodium retention with edema, and activation of the RAA system. The role of ANF in the pathophysiology of CHF remains to be defined. Circulating ANF is greatly increased in congestive heart failure. The mechanism of this elevation of ANF is explained by increased synthesis and release of ANF from the atria with atrial depletion of ANF in response to chronic atrial overload. Recent work also suggests the presence of ANF in ventricular myocardium in heart failure in which the ventricle is recruited to synthesize and release this peptide hormone. Despite increased circulating ANF in heart failure, the kidney retains sodium and is hyporesponsive to exogenous administration of ANF. The mechanism of this hyporesponsiveness is multifactorial but may be explained in part by activation of the intrarenal RAA system as well as by a reduction in renal perfusion pressure. A therapeutic role for ANF remaines unclear. To date, studies conflict, but some investigations of ANF infusions in man support a unique and selective renal vasodilator action in association with an ability to inhibit the RAA system.

Original languageEnglish (US)
JournalAmerican Journal of Hypertension
Volume1
Issue number4 Part II
StatePublished - 1988

Fingerprint

Atrial Natriuretic Factor
Heart Diseases
Renin-Angiotensin System
Heart Failure
Peptide Hormones
Sodium
Kidney
antiarrhythmic peptide
Vasodilator Agents
Edema
Myocardium
Arterial Pressure
Perfusion
Pressure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The atrial peptide system in cardiac disease. / Burnett, John C Jr.

In: American Journal of Hypertension, Vol. 1, No. 4 Part II, 1988.

Research output: Contribution to journalArticle

@article{36458a6e23ec40f4bf5cb0b91c308779,
title = "The atrial peptide system in cardiac disease",
abstract = "Atrial natriuretic factor (ANF) is a peptide hormone of cardiac origin, released in response to atrial distention, that increases sodium excretion, inhibits the renin-angiotensin-aldosterone (RAA) system, and decreases arterial pressure. Congestive heart failure (CHF) is a clinical syndrome that is characterized by chronic atrial distention, sodium retention with edema, and activation of the RAA system. The role of ANF in the pathophysiology of CHF remains to be defined. Circulating ANF is greatly increased in congestive heart failure. The mechanism of this elevation of ANF is explained by increased synthesis and release of ANF from the atria with atrial depletion of ANF in response to chronic atrial overload. Recent work also suggests the presence of ANF in ventricular myocardium in heart failure in which the ventricle is recruited to synthesize and release this peptide hormone. Despite increased circulating ANF in heart failure, the kidney retains sodium and is hyporesponsive to exogenous administration of ANF. The mechanism of this hyporesponsiveness is multifactorial but may be explained in part by activation of the intrarenal RAA system as well as by a reduction in renal perfusion pressure. A therapeutic role for ANF remaines unclear. To date, studies conflict, but some investigations of ANF infusions in man support a unique and selective renal vasodilator action in association with an ability to inhibit the RAA system.",
author = "Burnett, {John C Jr.}",
year = "1988",
language = "English (US)",
volume = "1",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "4 Part II",

}

TY - JOUR

T1 - The atrial peptide system in cardiac disease

AU - Burnett, John C Jr.

PY - 1988

Y1 - 1988

N2 - Atrial natriuretic factor (ANF) is a peptide hormone of cardiac origin, released in response to atrial distention, that increases sodium excretion, inhibits the renin-angiotensin-aldosterone (RAA) system, and decreases arterial pressure. Congestive heart failure (CHF) is a clinical syndrome that is characterized by chronic atrial distention, sodium retention with edema, and activation of the RAA system. The role of ANF in the pathophysiology of CHF remains to be defined. Circulating ANF is greatly increased in congestive heart failure. The mechanism of this elevation of ANF is explained by increased synthesis and release of ANF from the atria with atrial depletion of ANF in response to chronic atrial overload. Recent work also suggests the presence of ANF in ventricular myocardium in heart failure in which the ventricle is recruited to synthesize and release this peptide hormone. Despite increased circulating ANF in heart failure, the kidney retains sodium and is hyporesponsive to exogenous administration of ANF. The mechanism of this hyporesponsiveness is multifactorial but may be explained in part by activation of the intrarenal RAA system as well as by a reduction in renal perfusion pressure. A therapeutic role for ANF remaines unclear. To date, studies conflict, but some investigations of ANF infusions in man support a unique and selective renal vasodilator action in association with an ability to inhibit the RAA system.

AB - Atrial natriuretic factor (ANF) is a peptide hormone of cardiac origin, released in response to atrial distention, that increases sodium excretion, inhibits the renin-angiotensin-aldosterone (RAA) system, and decreases arterial pressure. Congestive heart failure (CHF) is a clinical syndrome that is characterized by chronic atrial distention, sodium retention with edema, and activation of the RAA system. The role of ANF in the pathophysiology of CHF remains to be defined. Circulating ANF is greatly increased in congestive heart failure. The mechanism of this elevation of ANF is explained by increased synthesis and release of ANF from the atria with atrial depletion of ANF in response to chronic atrial overload. Recent work also suggests the presence of ANF in ventricular myocardium in heart failure in which the ventricle is recruited to synthesize and release this peptide hormone. Despite increased circulating ANF in heart failure, the kidney retains sodium and is hyporesponsive to exogenous administration of ANF. The mechanism of this hyporesponsiveness is multifactorial but may be explained in part by activation of the intrarenal RAA system as well as by a reduction in renal perfusion pressure. A therapeutic role for ANF remaines unclear. To date, studies conflict, but some investigations of ANF infusions in man support a unique and selective renal vasodilator action in association with an ability to inhibit the RAA system.

UR - http://www.scopus.com/inward/record.url?scp=0023768189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023768189&partnerID=8YFLogxK

M3 - Article

C2 - 2973331

AN - SCOPUS:0023768189

VL - 1

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 4 Part II

ER -